Cell Genesys' New Data Bolster GVAX Survival Mechanism
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data increase chance of finding partner
You may also be interested in...
R&D IN BRIEF
Methylnaltrexone disappoints Wyeth; updates on cancer vaccines; More R&D news, in brief
Therapeutic Vaccine Trials Should Focus More On Patient Response – Study
A paradigm shift is needed in the field of therapeutic cancer vaccine trials that would evaluate patient response rather than tumor response, according to an analysis of prostate cancer vaccine trials in the July 1 issue of Clinical Cancer Research.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf